Oppenheimer restated their outperform rating on shares of Sutro Biopharma (NASDAQ:STRO – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The brokerage currently has a $10.00 target price on the stock. STRO has been the topic of a number of other reports. Piper Sandler reaffirmed an overweight rating and […]